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http://dx.doi.org/10.1016/j.ccr.2012.11.010SUMMARYThe androgen receptor (AR) regulates prostate cell growth in man, and prostate cancer is the commonest
cancer in men in the UK. We present a comprehensive analysis of AR binding sites in human prostate cancer
tissues, including castrate-resistant prostate cancer (CRPC). We identified thousands of AR binding sites in
CRPC tissue,most of which were not identified in PC cell lines. Many adjacent genes showedAR regulation in
xenografts but not in cultured LNCaPs, demonstrating an in-vivo-restricted set of AR-regulated genes. Func-
tional studies support a model of altered signaling in vivo that directs AR binding. We identified a 16 gene
signature that outperformed a larger in-vitro-derived signature in clinical data sets, showing the importance
of persistent AR signaling in CRPC.INTRODUCTION
Transcription factors (TFs) bind selectively to specific DNA
sequences and regulate developmental and pathogenic tran-
scriptional programs (Badis et al., 2009; Roche et al., 1992).
However, interactions between TFs can have a dramatic effect
on their genomic targeting, as in the case of FOXA1-dependent
recruitment of the androgen receptor (AR) and estrogen receptor
(ER) (Lupien et al., 2008) or STAT5-directed recruitment of theSignificance
This study confirms the importance of the AR in CRPC and show
positioning of the AR. It demonstrates a tissue-specific transcr
implications for our understanding and management of CRPC
otherwise not have been implicated in CRPC, has revealed p
of disease progression. This highlights the wider need to utili
factors by demonstrating the critical role of cellular context i
gene regulation.glucocorticoid receptor (Stoecklin et al., 1997) to specific tar-
gets. This interdependence and the diverse signals that affect
TF activity support a dynamic, context-dependent model for
their genomic targeting.
The study of oncogenic TFs has provided important mecha-
nistic insights into cancer biology (Hurtado et al., 2008; Palomero
et al., 2006; Wei et al., 2006). The AR is the main target of
hormonal therapies used in prostate cancer (PC), but despite
initial response to therapy, a large proportion of patients develops that cellular context is important in the functional genomic
iptional network not observed in cultured cells, with specific
. The core 16 gene set identified in this study, which would
otential targets for therapeutic intervention and monitoring
ze clinical material for the study of oncogenic transcription
n the regulation of transcription factor target selection and
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AR in Castration-Resistant Prostate Cancer in Mancastrate-resistant PC (CRPC), which leads to death in 12–
24 months. Many studies have described in detail the transcrip-
tional programs and pathways downstream of the AR, but the
authors used cultured cells with only selected ARBS tested in
tissue (Massie et al., 2011; Wang et al., 2009; Yu et al., 2010).
Application of these in-vitro-derived AR signatures to tissue-
expression profiles suggested a loss of AR signaling in CRPC
(Tomlins et al., 2007; Yu et al., 2010), a finding at odds with
both observations from functional studies (Chen et al., 2004;
Snoek et al., 2009) and the success of novel therapies targeting
AR signaling in CRPC (Attar et al., 2009; Attard et al., 2008; Tran
et al., 2009), suggesting that cell lines may not always accurately
model the AR transcriptional program in human tumors.
RESULTS
We mapped the genome-wide occupancy of the AR in prostate
tissue of 12 patients using chromatin immunoprecicpitation
sequencing (ChIP-seq). Samples were rich in epithelium (mean
67%), with the exception of androgen-deprivation treatment-
responsive (TR) samples, whichwere almost exclusively stromal.
AR expression was medium-high intensity in 9/10 PC samples,
but was absent or low in benign prostatic hyperplasia, and was
epithelial in all except for the TR samples (Table S1 and Figure S1
available online).
ARBS Can Be Identified in Human Prostate Tissue
AR-ChIP DNA was validated by assessing enrichment at known
AR binding sites (Figure 1A). Genome-wide AR-occupied re-
gions in 12 tissue samples were identified using ChIP-seq with
thousands of ARBS in human tissue (4,000 in at least two
samples), including established AR targets such as the KLK3
and TMPRSS2 enhancers (Figures 1A, 1B, and 1D). Pairwise
comparisons of AR binding profiles for tissue samples and three
unrelated PC cell lines (LNCaP, VCaP, 22RV1) highlighted two
clusters, reflecting (1) ARBS found predominantly in benign
and untreated PC tissue and (2) ARBS found in CRPC tissue
and cell lines (Massie et al., 2011) (Figure 1C). Benign samples
had significantly fewer ARBS than did CRPC samples (p <
0.02), which may reflect their lower levels of AR expression
(Table S1). TR samples also yielded low numbers of ARBS and
were the most divergent from the other AR binding profiles, re-
flecting stromal AR expression and absence of prostate epithe-
lium (Table S1). The highest correlations were between the
different PC cell lines, possibly reflecting their identical growth
conditions (Figure 1C). All commercially available cell lines that
have previously been characterized by AR ChIP-seq are derived
from metastatic deposits of PC and therefore might not accu-
rately reflect AR activity in primary PC, as there is substantial
evidence for altered expression profiles of androgen-regulated
genes inmetastatic versus primary PC (Glinsky et al., 2004; Tom-
lins et al., 2007; Varambally et al., 2005; Yu et al., 2004). Compar-
isons of ARBS identified in untreated andCRPC tissuewith those
in cultured PC cell lines revealed that these models were indeed
most similar to CRPC tissue (31% overlap, Table S2). Impor-
tantly, ARBS identified in untreated and CRPC tissue overlapped
by 30% (Table S2), while there was only a 3% overlap between
the ARBS in untreated PC tissue and cell lines (Table S2).
This highlights a common subset of AR target genes between36 Cancer Cell 23, 35–47, January 14, 2013 ª2013 Elsevier Inc.untreated PC and CRPC and identifies a divergence in AR
binding profiles between cultured cells and primary tissue.
A Unique AR Transcriptional Program Exists in PC
Tissue
Over 50% of ARBS identified in CRPC tissue were not found
in PC cell lines but were highly conserved and represented
tissue-specific sites, such as EIF2B5 (Figures 1E, 1F, and 2A).
Binding sites of histone marks H3K4me1 and H3K4me3 are
often used to classify sites that are associated with active tran-
scription from the rest of the sites in whole-genome TF data
sets; therefore, ChIP-seq of these marks was undertaken in an
additional two CRPC tissue samples. ChIP-seq of histone marks
H3K4me1 and H3K4me3 in CRPC tissue revealed overlapping
binding sites with the AR (26.2% of the AR peaks overlap with
H3K4 peaks in CRPC tissue; 0.81% of H3K4 peaks overlap
with AR peaks in CRPC tissue). The overlap between histone-
mark peaks and AR peaks was much lower in TR/untreated
tissue samples (17% and 4% for H3K4me1 and H3K4me3,
respectively) and with the AR in cultured cells (11% and 1% for
H3K4me1 and H3K4me3, respectively). The majority of genes
that show AR binding in CRPC tissue also have H3K4me1/me3
peaks (95% and 89%, respectively), further supporting the
activation of these AR target genes in vivo (Figures 1D and 1E).
Enrichment of H3K4me1 binding was identified at enhancers
and enrichment of H3K4me3 binding was identified at promoters
in all tissue samples (benign prostate tissue, TR PC, and CRPC
tissue) and was consistent with previous studies (Wang et al.,
2011; Yu et al., 2010) (Figures 2B and 2C).
Many of the genes adjacent to ARBS in CRPC tissue
showed androgen-regulated expression in cultured LNCaP
cells (Figure 3A), with preferential co-occurrence of the AR and
H3K4me3 observed at promoters of AR-regulated genes (ob-
served overlaps of 24% and 6% at AR-regulated genes and
AR-regulated gene promoters, compared to expected overlaps
of 5% and 2%, respectively, p = 2.99 3 1032 and p = 2.23 3
106). However, 44% of genes adjacent to CRPC ARBS showed
no evidence of AR regulation in LNCaP PC cell culture conditions
(Figure 3A). Importantly, the majority of these CRPC tissue AR
targets were differentially regulated in LNCaP xenografts fol-
lowing castration, including over one-third of genes that had
shown no androgen regulation in vitro (Figure 3B). The in vivo
regulation of these genes by the AR was further demonstrated
by differential expression in clinical samples from patients with
PC who were receiving neoadjuvant hormone treatment (Fig-
ure 3C), in an unrelated xenograft model (Figure 4A), and in clin-
ical samples from patients with untreated PC and CRPC in two
separate studies (Figures 4B and 4C).
In order to directly compare the in vitro and in vivo androgen
regulation of the AR bound genes identified in CRPC tissue,
we visualized gene-expression changes using two-dimensional
density plots (Shu et al., 2003; Venables and Ripley, 2002).
Genes bound by the AR in vitro (cell line ARBS within 25 kb)
had a strong shift toward androgen upregulation in vitro and
also evidence of downregulation in response to castration in
PC xenografts (Figure 4D). In contrast, genes bound by the AR
in vivo (CRPC tissue ARBS within 25 kb) showed an equally
strong in vivo response to castration but a markedly lesser
response to in vitro androgen stimulation (Figure 4D). This
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Figure 1. AR Binding Sites Mapped in Prostate Cancer Tissue Identify Divergent AR Binding Profiles In Vivo
(A) ChIP-PCR validation of known AR-regulated genes in CRPC-tissue AR ChIP, enrichment normalized to IgG control and relative to housekeeping genes
b-actin, GAPDH, and TBP.
(B) AR ChIP-seq enrichment profiles for benign, untreated prostate cancer (PC), castrate-resistant (CR) PC tissue, and LNCaP cells at the KLK3 (PSA) locus.
(C) Heatmap showing the concordance between AR ChIP sets from each tissue sample, cell line, and consensus binding sites (represented as percentage of set,
main subclusters highlighted by red boxes).
(D) Example of concordant binding in LNCaP cells and CRPC tissue of the AR and histone marks at the TMPRSS2 locus.
(E) Example of CRPC tissue AR binding and histone marks that were not found in cell lines at the EIF2B5 locus.
(F) Venn diagram showing the pairwise overlap between AR binding sites identified in cell lines (VCaP and LNCaP) and those in CRPC tissue.
See also Table S1 and Figure S1.
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AR in Castration-Resistant Prostate Cancer in Manin-vivo-restricted androgen regulation was highlighted in the
subset of AR targets identified in CRPC tissue that showed no
evidence of in vitro androgen regulation, where there was cleardownregulation in response to castration of PC xenografts (Fig-
ure 4D). Gene-expression changes in primary PC tumors treated
with neoadjuvant hormone therapy (NHT, chemical castration;Cancer Cell 23, 35–47, January 14, 2013 ª2013 Elsevier Inc. 37
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Figure 2. AR Binding Sites and Active Regulatory Elements Mapped in PC Tissue
(A) Average conservation plots of binding sites identified only in cell lines, only in CRPC tissue, and in both cell lines and CRPC tissue, for the AR, AR/H3K4me1
overlapping sites, and AR/H3K4me3 overlapping sites, using CEAS (Ji et al., 2006).
(B) Venn diagram showing overlap of H3K4me1/3 peaks from CRPC tissue in this study with those observed by Yu et al., 2010 and Wang et al., 2011.
(C) CEAS genomic analysis of histone mark binding sites identified in benign, TR (treatment-responding) PC, and CRPC tissue in this and other studies (Yu et al.,
2010; Wang et al., 2011).
See also Table S2.
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AR in Castration-Resistant Prostate Cancer in ManMostaghel et al., 2007) revealed that genes bound by the AR in
cultured PC cell lines showed little in vivo response to androgen
withdrawal (Figure 4E). However, AR targets identified in CRPC
tissue showed stronger gene-expression changes in response
to NHT therapy, further highlighted in the subset of genes that
showed no evidence of in vitro regulation (Figure 4E). Together
these data provide clear evidence for a subset of in-vivo-
restricted AR-regulated genes, supporting our identification of38 Cancer Cell 23, 35–47, January 14, 2013 ª2013 Elsevier Inc.functional AR targets in PC tissue and highlighting the diver-
gence from AR targets identified in cultured cells.
Divergent Transcriptional Complexes Are Present at
ARBS In Vitro and In Vivo
Genomic analysis of AR binding sites in CRPC tissue identified
higher enrichment at promoters compared to binding sites in
cell lines and in untreated PC tissue (Figure 5A), with untreated
AB
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Figure 3. AR Targets Identified in CRPC
Tissue Reveal In Vivo AR-Regulated Genes
(A) Gene-expression heatmaps showing LNCaP
in vitro androgen stimulation profiles of candidate
AR target genes identified in cell lines or CRPC
tissue (genes <25 kb from AR binding sites,
GSE18684). Subset of CRPC tissue AR targets not
androgen-regulated in vitro are plotted separately
(right).
(B) Gene expression heatmap from LNCaP PC
xenograft models from tumors in full and castrated
mice (unpublished data), subset as in (A).
(C) Gene-expression heatmap from a clinical trial
of neoadjuvant hormone therapy (NHT, acyline)
versus placebo (Mostaghel et al., 2007), subset
as in (A).
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AR in Castration-Resistant Prostate Cancer in ManPC tissue showing a shift toward higher intergenic binding, as
was seen in CRPC tissue, suggesting that the AR binding profile
in PC changes with disease progression. Motif analysis of the
ARBS identified in benign prostate tissue identified AR bindingCancer Cell 23, 35–4motifs as the only significantly enriched
motif, while in untreated PC the most en-
riched motifs included those for the AR,
forkhead, andNF1 TFs (Table S3). GREAT
analysis (McLean et al., 2010) revealed
that ARBS in untreated PC tissue were
enriched for genes involved in Notch,
MAPK, and calcium signaling and aerobic
respiration. These were not enriched
among benign ARBS, possibly reflecting
signaling and metabolic changes in the
progression to PC. ARBS found in PC
tissue were also enriched for genes asso-
ciated with metabolic stress (increased
cholesterol and increased body fat),
whereas ARBS from cultured cells were
most highly enriched for in vitro stimula-
tion with androgens and forskolin (Fig-
ure 5B). Genes upregulated in PC
samples and specific sets of metabolic
genes were enriched only near ARBS
found in CRPC tissue, suggesting a diver-
gent transcriptional program regulated by
the AR in CRPC tissue (Figure 5B).
Motif analysis of the genomic se-
quences underlying ARBS revealed sig-
nificant enrichment of consensus AR
bindingmotifs in both CRPC and cell lines
(Figure 6A; Table S3). However, AR
binding sites identified only in CRPC
tissue were enriched for E2F, MYC, and
STAT motifs (as were AR-H3K4me1/3
marked regions) but not for AR-associ-
ated TFs FOXA1 and NF-1, as previously
defined in tissue culture (Gao et al.,
2003; Jia et al., 2008) (Figures 6A and
6B). Comparisons of cell-line and tissue
ARBS with publicly available TF ChIP-seq data sets (Consortium, 2011) showed that ARBS identified
in tissue overlapped with E2F, MYC, STAT, NFKB, YY1, and
GATA binding sites, while ARBS in cell lines showed no enrich-
ment for these (Figure 6C). Additionally, genes associated with7, January 14, 2013 ª2013 Elsevier Inc. 39
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Figure 4. Surgical and Chemical Castration Regulate AR Target Genes Identified in PC Tissue
(A) Gene-expression heatmaps from KUCaP (Terada et al., 2010) PC xenograft models from tumors in full and castrated mice, subset by AR targets identified in
cell lines, AR targets identified in CRPC tissue, and those AR targets identified in tissue that are not AR-regulated in vitro.
(B) Gene-expression heatmaps showing human prostate tissue (benign, untreated, or CRPC) profiles of candidate AR targets identified in cell lines or CRPC
tissue.
(C) Gene-expression heatmap from hormone naive (HN) PC and CRPC (Best et al., 2005) showing AR target genes identified in CRPC tissue.
(D) Gene-expression changes in cultured LNCaPs treated with androgens (GSE18684) and KUCaP xenografts following castration (GSE21887) and NHT-treated
PC tumors (GSE8466), represented as two-dimensional density plots. Color changes represent the density of genes with a given expression pattern over the two
dimensions (as indicated on color scales), grouped as in (A).
(E)Gene-expressionchanges inNHT-treatedPCtumorsandKUCaPxenografts followingcastration representedas two-dimensionaldensityplots,groupedas in (A).
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AR in Castration-Resistant Prostate Cancer in ManARBS in PC tissue (<25 kb distant) were significantly enriched
(p < 0.05, FDR % 0.25) for genes regulated by MYC, E2F, and
IL6 (an activator of JAK/STAT) (Figure 6F).
To determine whether cellular context may contribute to the
observed change in AR binding profile between cultured cells
and CRPC tissue, we assessed AR interacting proteins in
cultured and xenografted LNCaP cells. This isogenic compar-
ison revealed an attenuated AR-FOXA1 interaction in xenografts,
in comparison with cultured cells, and also a gain of AR-STAT5
interaction in xenografts (Figures 6D and 6E). In addition, AR
binding could be redirected to sites only occupied by the AR in
PC tissue by treating cultured LNCaP cells with a cocktail of
cytokines, which have previously been implicated in PC (Fig-40 Cancer Cell 23, 35–47, January 14, 2013 ª2013 Elsevier Inc.ure 6G; see Supplemental Experimental Procedures for details).
We observed a clear increase in AR binding at 5/10 sites (p <
0.05) and a trend toward increased binding at a further 3/10 sites
tested (Figure 6G). Together these data provide functional vali-
dation of the altered AR binding profile observed in CRPC tissue
and provide insights into the molecular mechanisms that may
underlie these changes.
A Clinically Relevant Signature Is Identified from PC
Tissue
Wenext sought to test the utility of our PC tissue AR gene sets as
markers of function in vivo and as markers of CRPC and prog-
nosis. We identified a set of 150 AR target genes in CRPC tissue
AB
Figure 5. Distinct Transcriptional Targets of the AR and Downstream Signaling Pathways In Vitro and In Vivo
(A) Genomic location analysis of AR binding sites in LNCaP cell lines and CRPC and untreated PC tissue in comparison to the whole genome.
(B) GREAT (Genomic Regions Enrichment of Annotations Tool) analysis of AR binding sites identified in human tissue and cell lines, showing selected terms that
passed significance for one or more sets of AR binding sites.
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AR in Castration-Resistant Prostate Cancer in Manthat were downregulated by castration in PC xenografts and
were upregulated in CRPC tissue compared to untreated PC
(Figures 7A and 7B; Table S4). Gene-set enrichment of these
core 150 genes identified many of the same pathways as the
full set of AR targets in CRPC tissue (Table S4). Selection of
the genes with the most consistent changes across castrated
xenografts and CRPC identified a core 16 gene signature (Table
S4). All of these genes had increased expression in humanCRPC
tissue (Figure 7C) and all were downregulated by castration in
xenografts, with the reemergence of a subset in CRPC xeno-
grafts (Figure 7D). This core set of 16 AR target genes in CRPC
was enriched for E2F, STAT, and MYC binding sites (Consor-
tium, 2011) (Figure 7F), consistent with the full set of CRPC AR
binding sites (Figure 6). Gene-set analysis and direct comparison
of gene-expression changes showed that this core 16 gene sethad high gene-set enrichment scores for both in vitro AR-regu-
lated genes and xenograft castration-regulated genes, similar
to a published 250 gene ‘‘AR activity signature’’ (Mendiratta
et al., 2009) (Figure 7E), but overall showed a stronger correlation
with AR regulation in vivo (Figures 7E–7H; Figure S2). The core
CRPC AR signature also showed strong gene-set enrichment
for genes associated with CRPC and recurrent disease (p <
0.05 and FDR% 0.25, Figure 7E), together with overall upregula-
tion in CRPC tissue (Figure 7G), whereas the previously pub-
lished signature showed little enrichment (Figure 7E) and no
evidence of upregulation in CRPC (Figure 7G). These results
were supported by an orthologous analysis using multidimen-
sional scaling, which showed that the published AR gene signa-
ture (Mendiratta et al., 2009) captured more of the variance from
in vitro AR stimulation, whereas our core CRPC tissue 16 geneCancer Cell 23, 35–47, January 14, 2013 ª2013 Elsevier Inc. 41
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Figure 6. Divergent Transcriptional Complexes at AR Binding Sites In Vitro and In Vivo
(A) CEAS motif enrichment analysis of AR binding sites identified using ChIP-seq in PC cell lines (LNCaP and VCaP, Massie et al., 2011) and CR PC tissue.
(B) Sequence logos of transcription factor binding motifs enriched in cell line and CRPC tissue AR and histone-mark binding sites with enrichment p values,
generated in CEAS.
(C) Heatmap showing the cell-line and tissue AR target set overlap with publicly available ChIP data for other transcription factors (Consortium, 2011) (expressed
as % of set, annotated as ‘‘factor-cell line’’).
(D and E) AR immunoprecipitation (D) and STAT5 immunoprecipitation (E) in cultured and xenografted LNCaP PC cells, western blots of AR, FOXA1, and STAT5.
IgG controls and inputs are shown for each immunoprecipitation sequence.
(F) Gene-set enrichment analysis (GSEA) using genes within 25 kb of AR binding sites identified in either cell lines or CRPC tissue; *p < 0.05.
(G) Heatmap showing AR ChIP enrichment of CRPC tissue-specific AR targets following treatment of LNCaP cells with cytokine cocktail (see Supplemental
Experimental Procedures for details), enrichment normalized to IgG control and relative to housekeeping genes b-actin, GAPDH, and TBP.
See also Table S3.
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Figure 7. AR Signaling Is Maintained in Castrate-Resistant Prostate Cancer Tissue via a Distinct Set of AR Targets
(A) Scatter plot showing gene-expression changes of CRPC AR target genes in KUCaP xenografts (castrate/full) and clinical PC tissue (CRPC/PC) gene-
expression data (log fold change, M-values). Red-outlined rectangle denotes 150 genes down following castration and up in CRPC.
(B) Box plots for 150 selected genes using gene-expression data from clinical PC tissue and KUCaP xenografts.
(legend continued on next page)
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AR in Castration-Resistant Prostate Cancer in Manset performed better in both xenografts and PC tissue data sets
(Figure S2). This core set of CRPC AR targets was also sufficient
to faithfully segregate castrated from full PC xenografts and
hormone-therapy-treated PC from placebo-treated PC (Fig-
ure 7H). In addition, genes from this 16 gene set were able to
predict survival in two independent clinical data sets of PC (Glin-
sky et al., 2004, Taylor et al., 2010) (examples shown in Figure 7I).
We validated at the protein level a gene from this core signa-
ture, the tRNAmethyltransferase TRMT12, which showed strong
binding by the AR in CRPC tissue (Figure 8A) and exhibited in-
vivo-restricted AR regulation (Figures 8B and 8C). TRMT12
transcript was also upregulated in CRPC tissue (Figure 8D).
Immunohistochemistry revealed increased protein expression
in CRPC tissue compared to benign and untreated or TR PC
tissue both in samples taken from patients that were used for
AR ChIP-seq and in a separate cohort of patients (Figure 8E).
DISCUSSION
This study has successfully demonstrated a comprehensive
analysis of ARBS in a panel of human prostate tissue samples.
Combined analysis identified ARBS in untreated PC that were
lost in TR samples, a proportion of which were regained with
the emergence of CR disease. Integration of AR binding profiles
from cultured cells suggests that thesemodelsmaymore closely
reflect CR disease, in keeping with their metastatic origins.
Importantly, our combined analysis using prostate tissue identi-
fied a large number of ARBS not found in previous cell-line-
based studies.
AR targets identified in CRPC tissue allowed us to address
the apparently conflicting data on AR activity in CRPC. Using
an isogenic system we were able to identify in vitro and in vivo
AR-regulated genes, supporting direct AR regulation of the
CRPC tissue-specific AR targets. Further validation of these
targets using comparisons with an unrelated prostate cancer
xenograft model (Terada et al., 2010) and clinical gene-expres-
sion data from patients treated with neoadjuvant hormone
therapy provides evidence that the AR transcriptional program
in tissue is divergent from that in cultured cells. The ARBS iden-
tified in tissue correlated much better with clinical gene-expres-
sion data sets than did the ARBS from cell lines, suggesting that
tissue-derived data sets may more accurately reflect the in vivo
targets of the AR in PC patients.
The tissue-specific ARBS identified in CRPC, as compared to
cultured cells, are associated with in vivo androgen-regulated
genes and converge with distinct transcription factor networks.(C) Gene-expression heatmap showing LNCaP xenograft castration profiles of th
(D) Gene-expression heatmap showing segregation of CRPC samples from benig
target gene set identified in CRPC tissue.
(E) GSEA enrichment scores for genes in either the core 16 gene AR CRPC set o
expression data from in vitro AR activation (GSE18684), xenograft castration (G
*p < 0.05.
(F) Heatmap showing enrichment of core 16-gene signature in publicly-available
(G) Box plots showing gene expression changes from in vitro androgen stimulati
(GSE2443) using genes from our core 16 gene set or a published AR signature.
(H) Hierarchical clustering of castrated versus full xenografts and primary PC tu
Clustering was performed using the subset of genes in our core 16 gene CRPC
(I) Kaplan-Meier survival curves showing significant predictive ability of four core A
See also Figure S2 and Table S4.
44 Cancer Cell 23, 35–47, January 14, 2013 ª2013 Elsevier Inc.This difference in AR activity between cultured cells and primary
human tissue could be explained by genetic or epigenetic alter-
ations in regulators of AR cooperating transcription factors (e.g.,
FOXA1 mutations, RB inactivation, DAB2IP downregulation) or
by the integration of paracrine signaling events on other tran-
scription factors to modulate AR activity (Figures 8F and 8G).
Our functional studies in an isogenic system highlight the role
of altered signaling (Figures 6D and 6G), suggesting that differ-
ential expression and activation of AR-interacting transcription
factors contribute to the altered AR binding profile observed in
human PC tissue.
Overlapping binding sites of the AR and histone marks in
CRPC tissue and also the 16 gene signature we identified were
strongly enriched for STAT, MYC, and E2F binding sites (Figures
6C and 7F), supporting the importance of these pathways in the
progression and development of CRPC in man (Bernard et al.,
2003; Ellwood-Yen et al., 2003; Gao et al., 2009; Hedvat et al.,
2009; Sharma et al., 2010). We have demonstrated genomic re-
positioning of the AR in PC cells following treatment with a cyto-
kine cocktail that stimulates these critical pathways. We have
demonstrated in vitro versus in vivo changes in AR-interacting
proteins, which confirm our computational analysis and provide
a mechanistic explanation for the divergent AR binding profiles
seen in CRPC tissue compared to cultured cells. Our preliminary
functional studies highlight cellular context and altered cell sig-
naling as one possible mechanism and highlight the need for
detailed future studies to validate thesepathways and to carefully
address the transcription factor interplay in CRPC in vivo.
The divergent pathways identified in PC tissue and cultured
cells, supported by xenograft data, highlight a distinct transcrip-
tional program downstream of the AR targets in CRPC tissue,
wherein AR signaling regulates cellular processes that contribute
to both oncogenic and stem cell potential (e.g., proliferation,
metabolism, steroid biosynthesis).
The 16 gene signature identified in this studywas better able to
predict CRPC and recurrent PC than a larger published AR
signature, supporting the use in future TF studies of clinical
samples to determine clinically relevant information. This sig-
nature also highlights the utility of these targets as potential
markers of progression and response to therapy in CRPC, with
a subset of genes (including TNFSF10 and TM4SF1) significantly
predictive of survival in two independent clinical expression
data sets (Glinsky et al., 2004; Taylor et al., 2007). These gene
sets may be particularly useful in monitoring the efficacy of
second-generation agents targeting AR signaling when classical
markers such as prostate-specific antigen are lost.e core 16 AR CRPC gene set.
n and untreated hormone-naive PC samples (GSE28680) using the core 16 AR
r a larger in-vitro-derived AR activity signature (Mendiratta et al., 2009) using
SE21887), CRPC (GSE2443), and recurrent PC genes (Glinsky et al., 2004);
transcription factor ChIP data sets (Consortium, 2011).
on (GSE18684), xenograft castration (GSE21887)-regulated genes, and CRPC
mors treated with neoadjuvant hormone therapy (NHT-ACY) versus placebo.
AR set and the published in vitro AR activity signature.
R target genes, TM4SF1, SEC61A1, TNFSF10, and STIL (Glinsky et al., 2004).
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Figure 8. AR Signaling in Castrate-Resistant Prostate Cancer Tissue: Candidate Markers and Contributing Mechanism
(A) AR binding profile from cultured LNCaPs and CRPC tissue at the TRMT12 locus, as an example from the core 16 CRPC AR gene set.
(B) LNCaP in vitro androgen stimulation gene-expression profile for TRMT12.
(C) PC xenograft full and castrate gene expression of TRMT12.
(D) TRMT12 gene expression in clinical PC samples (benign, untreated, and castrate resistant).
(E) Immunohistochemistry for TRMT12 in benign and untreated, androgen-deprivation therapy-responding and castrate-resistant prostate cancer tissue (scale
bar represents 200 microns).
(F and G) Schematic showing possible models of divergent targeting of the AR in vitro (F) and in vivo (G).
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AR in Castration-Resistant Prostate Cancer in ManOur study provides insights into the pathways both up-
and downstream of AR signaling in prostate cancer tissue
and, importantly, has revealed functional and tissue-specifictargets of the AR in human CRPC. We have identified poten-
tial targets for therapeutic intervention, particularly with re-
spect to cell-cycle regulation and metabolism, and othersCancer Cell 23, 35–47, January 14, 2013 ª2013 Elsevier Inc. 45
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AR in Castration-Resistant Prostate Cancer in Manthat could be used to monitor disease progression. Many of
these tissue-specific AR targets are regulated by three other
major classes of TF (STAT, c-Myc, and E2F families), which
lie downstream of genetic alterations in PC (Sharma et al.,
2010) and paracrine signaling pathways implicated in CRPC
biology (Tam et al., 2007). Our study underscores the impor-
tance of cellular context in determining not only gene-expres-
sion patterns but also the binding profiles of specific TFs in
the study of disease.
EXPERIMENTAL PROCEDURES
Clinical Samples
All clinical samples were collected from Cambridge University Hospitals
NHS Trust as part of the ProMPT study, and ethical approval was granted
by the local research and ethics committee (LREC number: 02/281M) and by
the multicenter research and ethics committee (MREC number 01/4/061).
Informed consent was obtained from all subjects. Fresh tissue was obtained
at the time of transurethral resection of the prostate from ten patients with
PC (five castrate-resistant [CR], two androgen-deprivation-therapy responsive
[TR], and three untreated), and two men with benign prostate hyperplasia
(Table S1).
ChIP and Gene Expression
ChIP was performed as previously described (Massie et al., 2007; Schmidt
et al., 2008; Wilson et al., 2008), with enrichment tested by Realtime poly-
merase chain reaction using SYBRgreen (Applied Biosystems) (details in
Supplemental Experimental Procedures). Single-end SOLEXA libraries were
prepared as previously described (Schmidt et al., 2008), and 36 bp sequence
reads were generated and analyzed (details in Supplemental Experimental
Procedures). Details of RNA extraction and Illumina expression arrays are in
Supplemental Experimental Procedures.
Data Analysis
ARBS identified in individual PC tissue samples and cell lines were com-
pared by calculating the percentage overlap of BS (R1 bp overlap) for all
pairwise comparisons between samples, correlated using Eisen Cluster
(Eisen et al., 1998) and plotted as heatmaps. Overlap, subtraction, union,
and feature annotation of ChIP-seq enriched regions were done using the
Galaxy website (Blankenberg et al., 2007; Taylor et al., 2007). Motif-enrich-
ment analysis and evolutionary conservation of the ARBS identified in cell
lines and each tissue subtype were performed using CEAS (Ji et al., 2006).
Functional annotation of the genes associated with each of the ARBS was
performed using GREAT (McLean et al., 2010) and GSEA (Mootha et al.,
2003; Subramanian et al., 2005). ARBS were integrated with gene expression
data using a genomic window of 50 kb, and these genes were used to mine
publicly available expression data sets (details in Supplemental Experimental
Procedures). The core set of AR target genes in CRPC was identified by
using t tests to rank genes within 25 kb genomic windows of ARBS for
androgen-regulated expression (GSE18684) and expression in clinical PC
samples (GSE28680).
Cell Assays
Western blotting (AR, FOXA1, and STAT5) and coimmunoprecipitations (AR
and STAT5) were performed in LNCaP cells and xenografts (details in Supple-
mental Experimental Procedures).
Immunohistochemistry
Immunohistochemistry was performed using AR-N20 (Santa Cruz #sc-816)
and TRMT12 (Atlas #HPA023939) antibodies at 1:100 dilution.
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